163 related articles for article (PubMed ID: 34059352)
21. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
22. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapies for ROS1-rearranged non-small cell lung cancer.
Patil T; Simons E; Mushtaq R; Pacheco JM; Doebele RC; Bowles DW
Drugs Today (Barc); 2019 Oct; 55(10):641-652. PubMed ID: 31720561
[TBL] [Abstract][Full Text] [Related]
24. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
25. Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors.
Iyer SR; Nusser K; Jones K; Shinde P; Keddy C; Beach CZ; Aguero E; Force J; Shinde U; Davare MA
EMBO Mol Med; 2023 Oct; 15(10):e17367. PubMed ID: 37587872
[TBL] [Abstract][Full Text] [Related]
26. Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy.
Wachter F; Al-Ibraheemi A; Trissal MC; Hollowell M; DuBois SG; Collins NB; Church AJ; Janeway KA
Pediatrics; 2021 Dec; 148(6):. PubMed ID: 34814185
[TBL] [Abstract][Full Text] [Related]
27. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
28. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
29. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
30. Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report.
Velthaus JL; Iglauer P; Simon R; Bokemeyer C; Bannas P; Beumer N; Imbusch CD; Goekkurt E; Loges S
Oncol Res Treat; 2021; 44(9):495-502. PubMed ID: 34320493
[TBL] [Abstract][Full Text] [Related]
31. A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review.
Liu X; Duan Y; Wang G; Zhu P
Diagn Pathol; 2023 Sep; 18(1):105. PubMed ID: 37735390
[TBL] [Abstract][Full Text] [Related]
32. Lorlatinib for the treatment of patients with non-small cell lung cancer.
Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M
Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885
[TBL] [Abstract][Full Text] [Related]
33. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Keddy C; Shinde P; Jones K; Kaech S; Somwar R; Shinde U; Davare MA
Mol Cancer Ther; 2022 Feb; 21(2):336-346. PubMed ID: 34907086
[TBL] [Abstract][Full Text] [Related]
34. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
35. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.
Baranov E; Winsnes K; O'Brien M; Voss SD; Church AJ; Janeway KA; DuBois SG; Davis JL; Al-Ibraheemi A
Histopathology; 2022 Aug; 81(2):215-227. PubMed ID: 35543076
[TBL] [Abstract][Full Text] [Related]
36. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
37. Locally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review.
Durham C; Clemons M; Alias A; Konduri K
Cureus; 2022 Jul; 14(7):e27223. PubMed ID: 36035049
[TBL] [Abstract][Full Text] [Related]
38. First macrocyclic 3
Basit S; Ashraf Z; Lee K; Latif M
Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
40. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
Roys A; Chang X; Liu Y; Xu X; Wu Y; Zuo D
Cancer Chemother Pharmacol; 2019 Oct; 84(4):679-688. PubMed ID: 31256210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
